LONZA N | 562.20 / +1.19% |
Date/Time | 04/15 / 17:31 |
Chg. / Chg.(%) | 6.60 / +1.19% |
Bid | - / 110 |
Ask | - / 10 |
Open | 556.40 |
Previous Close | 555.60 |
High | 565.80 |
Low | 552.20 |
Volume [CHF] | 121,601,250.50 |
Volume [Units] | 216,666 |
Price fixings | 6863 |
ISIN | CH0013841017 |
Security | LONN |
Exchange | SIX Swiss Exchange |
Type | Stock |
Exchange | Last | Volume | |
---|---|---|---|
SIX Swiss Ex.. | 562.20 | ![]() |
216,666 |
Cboe Europe .. | 563.40 | ![]() |
31,666 |
Cboe Europe .. | 562.20 | ![]() |
17,470 |
London Inter.. | 560.62 | ![]() |
11,140 |
Turquoise | 563.60 | ![]() |
6,236 |
Nasdaq Other.. | 613.0000 | ![]() |
40 |
Lang & Schwa.. | 507.200 | ![]() |
|
Mexico | 12,110.20 | ![]() |
360 |
TradeGate | 294.000 | 298 | |
Frankfurt | 293.9000 | 63 | |
Düsseldorf | 291.20 | 0 | |
München | 291.30 | 0 | |
Berlin | 296.90 | 0 | |
Hamburg | 291.30 | 0 | |
gettex | 296.100 | ||
Singapore | 79.97 | 500 | |
EUREX | Options |
News
- aTyr Pharma and Lonza Announce Manufacturing Agreement for aTyr’s Anti-NRP2 Antibody ATYR2810
04/14/2021 / 14:00 - GlobeNewswire - Arbor Biotechnologies Names Devyn Smith, Ph.D., as CEO
04/01/2021 / 14:00 - GlobeNewswire - Altimmune Expands AdCOVID™ Manufacturing Collaboration with Lonza
03/12/2021 / 07:00 - GlobeNewswire - Arbor Biotechnologies Names Mark D. Angelino to its Board of Directors
03/03/2021 / 14:00 - GlobeNewswire - Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
01/12/2021 / 15:05 - GlobeNewswire